← Back to Search

Brain Stimulation

rTMS for Cannabis Use Disorder

N/A

Recruiting

Research Sponsored by Centre for Addiction and Mental Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline (pre-rtms), end of rtms (end of treatment week 4 of rtms), an average of 8 weeks from baseline assessment to end of rtms, follow-up (4-weeks post-rtms)

Awards & highlights

Study Summary

This trial will explore brain-based approach (rTMS) to treat cannabis use disorder (CUD), to reduce craving and consumption and improve executive function. It could provide the first widely adopted clinical rTMS intervention for CUD.

Who is the study for?

This trial is for adults aged 18-65 with cannabis use disorder, using cannabis at least 5 days a week and aiming to reduce or quit. They must have a certain level of dependency and be on stable psychiatric meds if any. Excluded are pregnant individuals, those with severe mental health disorders, other primary substance abuse issues, seizure history, significant head injury, unstable medical conditions, or specific medications.Check my eligibility

What is being tested?

The study tests repetitive transcranial magnetic stimulation (rTMS) using the MMC-140 coil on people with cannabis use disorder over four weeks. It will assess how well this non-invasive brain stimulation works in reducing cravings and consumption by exciting or inhibiting brain activity related to addiction.See study design

What are the potential side effects?

While rTMS is generally considered safe, potential side effects include discomfort at the treatment site, headache, lightheadedness, tingling sensations during scalp application or muscle contractions under the treatment coil.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline (pre-rtms), end of rtms (end of treatment week 4 of rtms), an average of 8 weeks from baseline assessment to end of rtms, follow-up (4-weeks post-rtms)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline (pre-rtms), end of rtms (end of treatment week 4 of rtms), an average of 8 weeks from baseline assessment to end of rtms, follow-up (4-weeks post-rtms)

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (pre-rtms), end of rtms (end of treatment week 4 of rtms), an average of 8 weeks from baseline assessment to end of rtms, follow-up (4-weeks post-rtms) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Feasibility of study completion as assessed by completion rates

Tolerability of Intervention as assessed by adverse event reporting

Secondary outcome measures

Anxiety symptoms

Cannabis Craving

Cannabis Use

+7 more

Trial Design

2Treatment groups

Active Control

Group I: High-Frequency (HF)Active Control1 Intervention

10 Hz rTMS

Group II: Low-Frequency (LF)Active Control1 Intervention

1 Hz rTMS

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Centre for Addiction and Mental HealthLead Sponsor

356 Previous Clinical Trials

81,398 Total Patients Enrolled

Brain & Behavior Research FoundationOTHER

61 Previous Clinical Trials

2,768 Total Patients Enrolled

Media Library

Repetitive Transcranial Magnetic Stimulation (Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT05859347 — N/A

Cannabis Use Disorder Research Study Groups: High-Frequency (HF), Low-Frequency (LF)

Cannabis Use Disorder Clinical Trial 2023: Repetitive Transcranial Magnetic Stimulation Highlights & Side Effects. Trial Name: NCT05859347 — N/A

Repetitive Transcranial Magnetic Stimulation (Brain Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05859347 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the trial accept individuals greater than thirty years old?

"All candidates applying for this clinical trial must be aged 18 or above and below 65."

Answered by AI

Is there still availability for individuals to join this experiment?

"The records housed on clinicaltrials.gov confirm that this medical study is actively enrolling patients, which began shortly after the May 15th 2023 posting date and was last edited 4 days prior."

Answered by AI

How many research participants have enrolled in this study?

"Indeed, the clinicaltrials.gov website indicates that this medical trial is recruiting patients. It was initially advertised on May 15th 2023 and has been recently updated on May 4th of the same year. The study aims to enrol 46 individuals from a single location."

Answered by AI

Who meets the necessary criteria to be eligible for this clinical investigation?

"The requirements for this experiment are cannabis use disorder and a age range between 18 to 65. A total of 46 individuals will be accepted into the study."

Answered by AI

What is the expected result of this experiment?

"The primary evaluation parameter of this research is the tolerability of the intervention, as indicated by adverse event reporting. Additional metrics to be monitored include cannabis cravings (using a 3-84 point scale), withdrawal symptoms, and depression severity (0-52 points). This analysis will span 8 weeks from baseline to end of rTMS treatment week 4, with outcome determined when participants withdraw from study."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder

2023. "Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05859347.

All > Transcranial Magnetic Stimulation